TITLE

GENEPORT DELIVERS SIX SYNTHETIC PROTEINS TO NORVARTIS

PUB. DATE
February 2002
SOURCE
Worldwide Biotech;Feb2002, Vol. 14 Issue 2, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Focuses on the synthetic proteins delivered by GeneProt Inc. to Novartis Pharma AG for pharmaceutical and diagnostic development purposes.
ACCESSION #
6395321

 

Related Articles

  • A heartening success.  // Supply Management;Oct2013, Vol. 18 Issue 10, p40 

    The article focuses on Novartis Pharma AG as the Best Cross-Functional Teamwork at the Chartered Institute of Purchasing and Supply's (CIPS) Supply Management Awards 2013 for the establishment of a robust supply chain for LCZ696, an active pharmaceutical ingredient for cadiovascular diseases.

  • Novartis awards top doctors in diabetes research.  // Drug Store News;7/22/2002, Vol. 24 Issue 9, p36 

    Presents the recipients of the 2002 Novartis Award in Diabetes for physicians who have demonstrated excellence in clinical research and diabetes education. Recipients of the Long-Standing Achievement Award and the Young Investigator Award.

  • Linebacker leads Novartis' charge. Tosh, Mark // Medical Marketing & Media;Dec2003, Vol. 38 Issue 12, p32 

    Reports on the designation of Kurt Graves as chief marketing officer of Novartis Pharma AG in the U.S. Career history of Graves; Expansion of the consumer research strategy; Responsibilities of Graves in the firm.

  • Novartis Gains New Foradil Indication. Krause, Carey // Chemical Market Reporter;10/08/2001, Vol. 260 Issue 13, p12 

    Reports that Novartis Pharma AG has received United States Food and Drug Administration approval for Foradil Aerolizer to treat chronic obstructive pulmonary disease (COPD). Rival products; Why Novartis says Foradil differs from other long-lasting β 2-agonists; Value of the market for the...

  • Oral Calcitonin Phase III in OA Patients Continues.  // Bioworld Week;8/2/2010, Vol. 18 Issue 31, p3 

    The article reports the continuation of the phase III study of Novartis Pharma AG on oral calcitonin in patients with osteoarthritis.

  • Aclasta receives marketing authorization.  // European Pharmaceutical Executive;Jul/Aug2005, p12 

    The article reports on the Marketing Authorization granted by the European Commission to Aclasta for the treatment of Paget's disease of the bone in all 25 European member states, according to manufacturer Novartis Pharma AG. A single infusion of Aclasta for 15 minutes indicated a faster and...

  • Financings Roundup.  // BioWorld Today;2/25/2010, Vol. 21 Issue 37, p7 

    The article reports on the decision of Novartis Pharma AG to extend the maturity date of the convertible promissory note of Emisphere Technologies Inc. to May 26, 2010.

  • GENEPROT/ZYMARK SIGN AUTOMATION PACT FOR U.S./EUROPE.  // Worldwide Biotech;Apr2002, Vol. 14 Issue 4, p5 

    Reports that GeneProt Inc. and Zymark Corp. have entered into an agreement in which Zymark is named as an exclusive automation provider to GeneProt in the U.S. and Europe.

  • Swiss proteomics company aims to make big impact. Abbott, Alison // Nature;4/19/2001, Vol. 410 Issue 6831, p856 

    Announces the opening of the GeneProt company in Geneva, Switzerland, on April 26, 2001. Aim of the company in relation to proteomics; Nature of its business.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics